Lexicon Q3 2025 net loss narrows to $12.8M; pipeline advances with FDA milestones on track

LEXICON PHARMACEUTICALS, INC.

2025-Q3 EPS reported -$0.10 revenue$44,310,000

Q3 revenue $14.2M (from $1.8M YoY) driven by $13.2M Novo Nordisk licensing; net loss $12.8M vs $64.8M prior year.
Cash and investments $145M as of Sep 30, down from $238M at Dec 31, 2024, but company says strong footing.
End-of-Phase 2 meeting for pilavapadin (DPNP) with FDA scheduled by year-end; partnership discussions ongoing.
LX9851 IND-enabling studies completed and handed to Novo Nordisk; near-term milestone potential $30M.
SONATA-HCM Phase 3 enrollment on target for 2026; 130 sites initiated. Zynquista resubmission feedback expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.